Immunic, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
Immunic, Inc. (IMUX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of 35.41 thousand shares for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-05-09.
Discontinued › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2017-05-09
- Immunic, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2017-03-31 was 35.41K shares, a 17.30% increase year-over-year.
- Immunic, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2016-12-31 was 18.50K shares, a 97.52% decline year-over-year.
- Immunic, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2016-09-30 was 67.17K shares, a 7.43% decline year-over-year.
- Immunic, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2016-06-30 was 1.09M shares, a 1745.56% increase year-over-year.
- Immunic, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2016 was 1.21M shares, a 27.93% increase from fiscal 2015.
- Immunic, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2015 was 942.28K shares, a 188.76% increase from fiscal 2014.
- Immunic, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2014 was 326.32K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month |
|---|---|---|---|---|
| 2017-03-31 | 35.41K shares 10-Q · filed 2017-05-09 | 53.91K shares derived: sum of 2 quarters · filed 2017-05-09 | 121.08K shares derived: sum of 3 quarters · filed 2017-05-09 | 1.21M shares derived: sum of 4 quarters · filed 2017-05-09 |
| 2016-12-31 | 18.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-07 | 85.67K shares derived: sum of 2 quarters · filed 2017-03-07 | 1.18M shares derived: sum of 3 quarters · filed 2017-03-07 | 1.21M shares 10-K · filed 2017-03-07 |
| 2016-09-30 | 67.17K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | 1.16M shares derived: sum of 2 quarters · filed 2016-11-03 | 1.19M shares 10-Q · filed 2016-11-03 | 1.93M shares derived: sum of 4 quarters · filed 2016-11-03 |
| 2016-06-30 | 1.09M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-02 | 1.12M shares 10-Q · filed 2016-08-02 | 1.87M shares derived: sum of 3 quarters · filed 2016-08-02 | 1.94M shares derived: sum of 4 quarters · filed 2016-08-02 |
| 2016-03-31 | 30.18K shares 10-Q · filed 2016-05-09 | 777.17K shares derived: sum of 2 quarters · filed 2016-05-09 | 849.74K shares derived: sum of 3 quarters · filed 2016-05-09 | 908.78K shares derived: sum of 4 quarters · filed 2016-05-09 |
| 2015-12-31 | 746.99K shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-08 | 819.55K shares derived: sum of 2 quarters · filed 2016-03-08 | 878.59K shares derived: sum of 3 quarters · filed 2016-03-08 | 942.28K shares 10-K · filed 2016-03-08 |
| 2015-09-30 | 72.57K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | 131.61K shares derived: sum of 2 quarters · filed 2015-11-05 | 195.29K shares 10-Q · filed 2015-11-05 | 310.37K shares derived: sum of 4 quarters · filed 2015-11-05 |
| 2015-06-30 | 59.04K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | 122.72K shares 10-Q · filed 2015-08-06 | 237.80K shares derived: sum of 3 quarters · filed 2015-08-06 | 327.19K shares derived: sum of 4 quarters · filed 2015-08-06 |
| 2015-03-31 | 63.68K shares 10-Q · filed 2015-05-12 | 178.76K shares derived: sum of 2 quarters · filed 2015-05-12 | 268.14K shares derived: sum of 3 quarters · filed 2015-05-12 | 328.35K shares derived: sum of 4 quarters · filed 2015-05-12 |
| 2014-12-31 | 115.08K shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-20 | 204.46K shares derived: sum of 2 quarters · filed 2015-03-20 | 264.67K shares derived: sum of 3 quarters · filed 2015-03-20 | 326.32K shares 10-K · filed 2015-03-20 |
| 2014-09-30 | 89.38K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | 149.59K shares derived: sum of 2 quarters · filed 2014-11-13 | 211.25K shares 10-Q · filed 2014-11-13 | |
| 2014-06-30 | 60.21K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | 121.86K shares 10-Q · filed 2014-08-07 | ||
| 2014-03-31 | 61.65K shares 10-Q · filed 2014-05-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B |